The race is on amongst the international scientific research community to develop a vaccine that will prevent infection by SARS-CoV-2, the virus that causes COVID-19. There is also the very real risk of a second wave of Coronavirus infection in countries that have already been badly hit earlier in 2020, as autumn looms. By the end of 2021, the World Health Organisation (WHO) plans to deliver over 2 billion doses of a Coronavirus vaccine internationally to accelerate herd immunity and wipe out the highly infectious virus. Rich Quelch at Origin explains why this ambitious timeline presents a huge challenge for pharmaceutical supply chains and healthcare systems.